NSAIDs and cardiovascular risk

Journal of Cardiovascular Medicine

Volumn 18, Issue , 2017, Pages e40-e43

  Marsico, Fabio ^a   Paolillo, Stefania ^a   Filardi, Pasquale P ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cardiovascular events; Cardiovascular risk; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARTERY EMBOLISM; ATRIAL FIBRILLATION; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE; CHEMICALLY INDUCED; META ANALYSIS (TOPIC); RISK;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; HUMANS; META-ANALYSIS AS TOPIC; RISK;

EID: 84988628639     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000443     Document Type: Conference Paper

References (37)

1. Fosbøl EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010; 3:395-405.
2. Marsico F, Gargiulo P, Parente A, et al. Ischemic heart disease in systemic inflammatory diseases. An appraisal. Int J Cardiol 2014; 170:286-290.
3. Marsico F, Parente A, Paolillo S, et al. Cardiovascular risk in systemic inflammatory diseases. G Ital Cardiol (Rome) 2013; 14:517-525.
4. Schaffer D, Florin T, Eagle C, et al. Risk of serious NSAID-related gastrointestinal events during long-term exposure: A systematic review. Med J Aust 2006; 185:501-506.
5. Scott PA, Kingsley GH, Smith CM, et al. Nonsteroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 2007; 66:1296-1304.
6. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. New Engl J Med 2001; 345:433-442.
7. Campbell CL, Moliterno DJ. Potential hazards of adding nonsteroidal antiinflammatory drugs to antithrombotic therapy after myocardial infarction: time for more than a gut check. JAMA 2015; 313:801-802.
8. Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci 2013; 16:821-847.
9. Kohli P, Steg PG, Cannon CP, et al. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. Am J Med 2014; 127:53-60.
10. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New Engl J Med 2000; 343:1520-1528.
11. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364:665-674.
12. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl J Med 2005; 352:1092-1102.
13. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med 2005; 352:1071-1080.
14. Nussmeier NA, Whelton AA, Brown MT. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352:11.
15. Kerr DJ, Dunn JA, Langman MJ. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007; 357:360-369.
16. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006; 332:1302-1308.
17. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006; 98:266-274.
18. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA 2006; 296:1633-1644.
19. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of nonsteroidal anti-inflammatory drugs: network meta-analysis. Br Med J 2011; 342:c7086.
20. Cannon CP, Cannon PJ. Physiology. Cox-2 inhibitors and cardiovascular risk. Science 2012; 336:1386-1387.
21. Yu Y, Ricciotti E, Scalia R, et al. Vascular Cox-2 modulates blood pressure and thrombosis in mice. Sci Transl Med 2012; 4:132-154.
22. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 1984; 310:347-352.
23. Feenstra J, Heerdink ER, Grobbee DE, Stricker BH. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: The Rotterdam Study. Arch Intern Med 2002; 162:265-270.
24. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165:490-496.
25. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal antiinflammatory drugs in chronic heart failure. Arch Intern Med 2009; 169:141-149.
26. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345:1809-1817.
27. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2:637-643.
28. Singh G, Miller JD, Huse DM, Pettitt D, D'Agostino RB, Russell MW. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol 2003; 30:714-719.
29. Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA 2015; 313:805-814.
30. Lamberts M, Lip GY, Hansen ML, et al. Relation of nonsteroidal antiinflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy a nationwide cohort study. Ann Intern Med 2014; 161:690-698.
31. Olsen AM, Fosbøl EL, Lindhardsen J, et al. Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction a nationwide cohort study. Circulation 2012; 126:1955-1963.
32. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Circulation 2006; 113:2906-2913.
33. Bhala N, Emberson J, Merhi A, et al., Coxib and Traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382:769-779.
34. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009; 2:155-163.
35. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64:e139-e228.
36. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: A scientific statement from the American Heart Association. Circulation 2007; 115:1634-1642.
37. McGettigan P, Henry D. Use of nonsteroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 2013; 10:e1001388.